Pee Safe, a prominent personal hygiene brand, has successfully secured $32 million (₹290 crore) in a Series C funding round. This substantial investment comes from global healthcare-focused private equity firm OrbiMed Asia Partners, alongside participation from existing investors. The company confirmed that the funding round involved both primary and secondary shares, a strategic move aimed at fueling its ambitious growth plans.

The fresh capital infusion is earmarked for several key initiatives. Pee Safe intends to significantly expand its offline retail footprint, thereby increasing its physical presence in the market. A considerable portion will also be allocated to strengthening brand-led marketing efforts to enhance brand visibility and consumer engagement. Furthermore, the company plans to broaden its reach across various quick commerce platforms and online marketplaces, ensuring wider availability of its diverse product portfolio to a larger customer base.

Pee Safe's comprehensive product range encompasses various categories, including toilet hygiene, feminine and intimate hygiene, personal care, grooming, and wellness. Currently, the brand boasts a strong presence in approximately 50,000 retail outlets spread across 100 cities. In addition to its extensive offline network, Pee Safe products are readily available on leading e-commerce and quick commerce platforms, catering to the evolving shopping habits of modern consumers.

Vikas Bagaria, the founder of Pee Safe, emphasized the brand's foundational mission: "Pee Safe was founded to address a deeply underserved women's health category and challenge long-standing taboos." He highlighted that this core focus has resulted in a business built on robust fundamentals, with its ability to scale profitably reflecting a disciplined and long-term strategic approach. Bagaria expressed optimism about the partnership with OrbiMed, noting that they share a similar conviction in the consumer healthcare opportunity, marking a crucial step in Pee Safe's next growth phase.

Financially, Pee Safe has demonstrated impressive growth, scaling to over ₹150 crore in annualized net revenue. In the fiscal year 2025 (FY25), the company reported revenue from operations of ₹82 crore, marking a significant 46% increase from ₹56 crore in the previous year. Concurrently, the brand successfully narrowed its loss to a mere ₹4 crore, indicating improved operational efficiency and a path towards profitability.

Prior to this latest Series C round, Pee Safe had already raised a total of $16.5 million, with Alkemi Growth Capital leading as its primary investor, as per data from Traxcn. More recently, in 2023, the company secured $3 million in funding from a group of investors led by Natco Pharma and Rainmatter Health.

In conjunction with the new investment, OrbiMed's senior managing director, Sunny Sharma, and executive director, Sumona Chakraborty, will join Pee Safe’s board. OrbiMed is a global healthcare-focused private equity firm that manages approximately $20 billion across public and private company investments worldwide, operating through offices in key healthcare hubs. The firm has a track record of strategic investments in the healthcare sector, including its investments in ayurvedic wellness brand Kapiva in 2024, medtech firm Innvolution Healthcare, and generic drugmaker Marksans Pharma in 2023, among others.